Form 4: HeartSciences CEO Simpson Boosts Stake with 70,000 Share Grant

HeartSciences Inc. CEO Andrew Simpson was granted 70,000 shares of common stock under the company's 2023 Equity Incentive Plan, increasing his beneficial ownership to 74,382 shares.

Summary

• Andrew Simpson, Chairman of the Board, President, and Chief Executive Officer of HeartSciences Inc., acquired 70,000 shares of common stock.
• The shares were granted on November 28, 2025, under the Issuer's 2023 Equity Incentive Plan, as approved by the board of directors.
• Following this transaction, Simpson beneficially owns a total of 74,382 shares of common stock.
• Vesting of the shares is contingent upon the approval of an amendment or modification to the Plan and a time-based schedule.
• One-third of the shares will vest on the one-year anniversary of the grant date, with 1/12th vesting on each subsequent quarterly anniversary until fully vested on the three-year anniversary.
• Accelerated 100% vesting will occur upon a Change of Control or if the Issuer achieves $250,000 or more in revenue in any fiscal quarter.

Sentiment

Score: 7

Explanation: The grant of shares to the CEO is a positive sign of management alignment and long-term commitment, with performance incentives. However, the vesting contingency on plan amendment approval introduces a minor uncertainty.

Positives

• The grant of 70,000 shares to the CEO aligns management's interests with shareholders, promoting long-term value creation.
• Performance-based vesting, tied to a revenue target of $250,000 in a fiscal quarter, incentivizes significant company growth and commercial success.
• The three-year vesting schedule, contingent on continuous employment, acts as a strong retention mechanism for key leadership.

Negatives

• Vesting of the shares is contingent on the future approval of an amendment or modification to the 2023 Equity Incentive Plan, introducing a potential uncertainty.
• The specific grant price for the shares was not disclosed, though it is an equity incentive award.

Risks

• The vesting of the granted shares is subject to the satisfaction of a condition precedent: the approval of any amendment or modification to or restatement of the 2023 Equity Incentive Plan.
• The company faces the risk of not achieving the $250,000 revenue target in a fiscal quarter, which would prevent accelerated vesting of the shares.
• The value of the granted shares is inherently subject to market fluctuations and the overall financial performance of HeartSciences Inc.

Future Outlook

The filing indicates a forward-looking incentive structure tied to the company's 2023 Equity Incentive Plan, with a clear revenue target of $250,000 in a fiscal quarter designed to accelerate vesting and incentivize growth. The vesting schedule extends over three years, suggesting a long-term retention strategy for the CEO.

Management Comments

• These shares of common stock were granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan pursuant to the approval of the Issuer's board of directors.
• The Shares shall vest subject to the satisfaction of all of the following conditions: (i) approval of any amendment or modification to or restatement of the Plan... and (ii)(x) 1/3rd of the Shares shall vest on the one year anniversary of the grant date... and (y) thereafter, 1/12th of the Shares shall vest on each subsequent quarterly anniversary...
• 100% of the Shares shall vest (i) in the event of a Change of Control... or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof.

Industry Context

This Form 4 filing reflects a common practice in the healthcare technology or medical device industry, where executive compensation often includes equity grants to align leadership incentives with long-term company performance and shareholder value. The revenue target for accelerated vesting suggests a focus on commercialization and market penetration, which is typical for companies in growth phases within this sector.

Comparison to Industry Standards

• Equity grants to CEOs are standard practice across industries, including healthcare tech, to incentivize performance and retention.
• Vesting schedules over 3-4 years are common, aligning with long-term strategic goals.
• Performance-based vesting conditions, such as revenue targets, are increasingly used to link executive compensation directly to measurable business achievements, similar to practices at companies like Medtronic or Intuitive Surgical for their executive incentive plans, though the specific revenue target of $250,000 is specific to HeartSciences' current stage.
• Change of Control clauses for accelerated vesting are also standard in executive compensation agreements to protect executives in acquisition scenarios.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of CEO's interests with long-term company performance and value creation.
• Management: Andrew Simpson's compensation structure is enhanced, providing strong incentives for retention and performance.

Next Steps

• Approval of any amendment or modification to or restatement of the 2023 Equity Incentive Plan.
• Achievement of $250,000 or more in revenue in any fiscal quarter for accelerated vesting.
• Continued employment of Andrew Simpson through vesting dates.

Key Dates

Recommendation

This Form 4 filing details a standard equity grant to the CEO as part of an approved incentive plan. While it aligns management's interests with shareholders and includes performance incentives, it does not present new information that would fundamentally alter the investment thesis for HeartSciences Inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future operational and financial performance.

Keywords

HeartSciences Inc., HSCS, Andrew Simpson, Form 4, Insider Ownership, Equity Incentive Plan, Stock Grant, CEO Compensation, Vesting, Corporate Governance, SEC Filing